Cue Biopharma
Stock Forecast, Prediction & Price Target
Cue Biopharma (CUE) stock Price Target by analysts
$4
Potential upside: 393.76%
Cue Biopharma price prediction
What is Cue Biopharma stock analysts` prediction?
Cue Biopharma stock forecast: Based on 1 Wall Street analysts` predicted price targets for Cue Biopharma in the last 3 months, the avarage price target is $4, with a high forecast of $NaN. The average price target represents a 393.76% change from the last price of $0.81.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Cue Biopharma stock Price Target by analysts
Full breakdown of analysts given Cue Biopharma price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Maury Raycroft Jefferies | 0% 0/2 | 11 months ago | $4 393.76% upside | $1.29 | StreetInsider | Previous targets (1) |
Reni Benjamin JMP Securities | 0% 0/1 | about 1 year ago | $2 146.88% upside | $0.7 | TheFly | Previous targets (0) |
Maury Raycroft Jefferies | 0% 0/2 | over 1 year ago | $6 640.64% upside | $2.15 | StreetInsider | Previous targets (1) |
Edward Tenthoff Piper Sandler | 0% 0/1 | almost 3 years ago | $7 764.09% upside | $3.22 | TheFly | Previous targets (0) |
Cue Biopharma Financial Estimates
Cue Biopharma Revenue Estimates
Cue Biopharma EBITDA Estimates
Cue Biopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $14.94M N/A | $1.24M -91.66% | $5.49M 340.88% | Avg: $14.69M Low: $2.13M High: $48.08M avg. 167.62% | Avg: $19.45M Low: $5.16M High: $47.93M avg. 32.39% | Avg: $77.59M Low: $20.59M High: $191.18M avg. 298.87% | Avg: $190.06M Low: $50.43M High: $468.30M avg. 144.95% |
Net Income
% change YoY
| $-44.16M N/A | $-52.79M -19.55% | $-50.73M 3.90% | Avg: $-62.74M Low: $-72.75M High: $-21.50M avg. -23.67% | Avg: $-69.97M Low: $-68.17M High: $-32.48M avg. -11.53% | Avg: $-16.01M Low: $-46.49M High: $-720.43K avg. 77.11% | Avg: $45.44M Low: $2.04M High: $131.94M avg. 383.80% |
EBITDA
% change YoY
| $-43.71M N/A | $-50.76M -16.13% | $-46.05M 9.28% | Avg: $-14.69M Low: $-48.08M High: $-2.13M avg. 68.09% | Avg: $-19.45M Low: $-47.93M High: $-5.16M avg. -32.39% | Avg: $-77.59M Low: $-191.18M High: $-20.59M avg. -298.87% | Avg: $-190.06M Low: $-468.30M High: $-50.43M avg. -144.95% |
EPS
% change YoY
| -$1.41 N/A | -$1.48 -4.96% | -$1.11 24.99% | Avg: -$1 Low: -$1.59 High: -$0.47 avg. 9.54% | Avg: -$1.05 Low: -$1.49 High: -$0.71 avg. -4.91% | Avg: -$0.35 Low: -$1.02 High: -$0.02 avg. 66.77% | Avg: $0.99 Low: $0.04 High: $2.88 avg. 383.80% |
Operating Expenses
% change YoY
| $58.65M N/A | $54.74M -6.66% | $19.54M -64.30% | Avg: $73.40M Low: $10.67M High: $240.23M avg. 275.62% | Avg: $97.18M Low: $25.79M High: $239.46M avg. 32.39% | Avg: $387.65M Low: $102.87M High: $955.15M avg. 298.87% | Avg: $949.57M Low: $251.99M High: $2.33B avg. 144.95% |
FAQ
What is Cue Biopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 106.43% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -72.75M, average is -62.74M and high is -21.50M.
What is Cue Biopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 160.96% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $2.13M, average is $14.69M and high is $48.08M.
What is Cue Biopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 113.80% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.59, average is -$1 and high is $-0.47.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Cue Biopharma stock. The most successful analyst is Maury Raycroft.